MX377044B - Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos. - Google Patents
Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos.Info
- Publication number
- MX377044B MX377044B MX2017007458A MX2017007458A MX377044B MX 377044 B MX377044 B MX 377044B MX 2017007458 A MX2017007458 A MX 2017007458A MX 2017007458 A MX2017007458 A MX 2017007458A MX 377044 B MX377044 B MX 377044B
- Authority
- MX
- Mexico
- Prior art keywords
- fgf21
- derivatives
- growth factor
- fibroblast growth
- relates
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title abstract 6
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title abstract 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 2
- 108091008794 FGF receptors Proteins 0.000 abstract 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 abstract 1
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 102000056713 human FGF21 Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199935 | 2014-12-23 | ||
| PCT/EP2015/080969 WO2016102562A1 (en) | 2014-12-23 | 2015-12-22 | Fgf21 derivatives and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017007458A MX2017007458A (es) | 2017-08-10 |
| MX377044B true MX377044B (es) | 2025-03-07 |
Family
ID=52130150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007458A MX377044B (es) | 2014-12-23 | 2015-12-22 | Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos. |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9744213B2 (enExample) |
| EP (1) | EP3236991B1 (enExample) |
| JP (1) | JP6727210B2 (enExample) |
| KR (1) | KR102427527B1 (enExample) |
| CN (1) | CN107108709B (enExample) |
| AR (1) | AR103246A1 (enExample) |
| AU (1) | AU2015371056B2 (enExample) |
| DK (1) | DK3236991T3 (enExample) |
| ES (1) | ES2742503T3 (enExample) |
| HK (1) | HK1246156B (enExample) |
| HR (1) | HRP20191292T1 (enExample) |
| HU (1) | HUE044783T2 (enExample) |
| IL (1) | IL252438B (enExample) |
| MX (1) | MX377044B (enExample) |
| MY (1) | MY181181A (enExample) |
| PL (1) | PL3236991T3 (enExample) |
| PT (1) | PT3236991T (enExample) |
| RS (1) | RS59154B1 (enExample) |
| RU (1) | RU2729011C2 (enExample) |
| SA (1) | SA517381673B1 (enExample) |
| SI (1) | SI3236991T1 (enExample) |
| TW (2) | TWI681966B (enExample) |
| WO (1) | WO2016102562A1 (enExample) |
| ZA (1) | ZA201703768B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45113A (fr) | 2016-05-24 | 2019-04-10 | Novo Nordisk As | Composés mic-1 et leur utilisation |
| CN106421753A (zh) * | 2016-10-19 | 2017-02-22 | 哈尔滨医科大学 | 重组人成纤维细胞生长因子‑21在制备预防和治疗缺血性心律失常药物中的应用 |
| TWI710377B (zh) * | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| CA3074380C (en) | 2017-09-04 | 2023-01-03 | 89Bio Ltd. | Mutant fgf-21 peptide conjugates and uses thereof |
| US12226451B2 (en) | 2018-07-03 | 2025-02-18 | Bristol-Myers Squibb Company | FGF-21 formulations |
| US11427623B1 (en) | 2019-05-28 | 2022-08-30 | 89Bio Ltd. | Methods of treatment using mutant FGF-21 peptide conjugates |
| CN115322794B (zh) | 2020-01-11 | 2025-09-19 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
| EP4337681A1 (en) | 2021-05-11 | 2024-03-20 | Cytoki Pharma ApS | Therapeutic derivatives of interleukin-22 |
| EP4089108A1 (en) | 2021-05-11 | 2022-11-16 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| KR102631925B1 (ko) * | 2021-06-10 | 2024-02-01 | 토드제약 주식회사 | 신규 fgf21 변이체 개발 및 이의 생산기법과 용도 |
| CA3224743A1 (en) | 2021-07-14 | 2023-01-19 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion polypeptides for metabolic disorders |
| AU2022341345A1 (en) * | 2021-09-08 | 2024-03-28 | Leto Laboratories Co., Ltd | Fgf21 mutant protein and use thereof |
| KR102749341B1 (ko) | 2022-07-08 | 2025-01-06 | 노보 노르디스크 에이/에스 | FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물 |
| AU2023303873A1 (en) | 2022-07-08 | 2025-01-02 | Novo Nordisk A/S | Highly potent isvd compounds capable of substituting for fviii(a) |
| WO2024199734A2 (en) | 2023-03-30 | 2024-10-03 | Novo Nordisk A/S | Fusion compounds and uses thereof |
| AU2024272220A1 (en) * | 2023-05-12 | 2025-10-16 | Novo Nordisk A/S | Long-acting growth hormone receptor antagonist and use thereof |
| AR133774A1 (es) | 2023-09-11 | 2025-10-29 | Novo Nordisk As | Anticuerpos de dominio anti-il-6 |
| CN118307684B (zh) * | 2024-06-11 | 2024-10-18 | 北京志道生物科技有限公司 | 一种经脂肪酸链修饰的glp-1-fgf21融合蛋白及其制备方法和应用 |
| WO2026012311A1 (zh) * | 2024-07-08 | 2026-01-15 | 浙江道尔生物科技有限公司 | Fgf21衍生物及其用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
| EP1329227A1 (en) | 2002-01-22 | 2003-07-23 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells |
| EA008831B1 (ru) | 2003-06-12 | 2007-08-31 | Эли Лилли Энд Компани | Слитые белки аналогов glp-1 |
| JP2007537981A (ja) | 2003-09-19 | 2007-12-27 | ノボ ノルディスク アクティーゼルスカブ | 新規の血漿タンパク質親和性タグ |
| CA2539253A1 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| AU2004303783A1 (en) | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| BRPI0417684A (pt) | 2003-12-18 | 2007-03-20 | Novo Nordisk As | composto, composição farmacêutica, e, uso de um composto |
| JP2007531715A (ja) | 2004-03-17 | 2007-11-08 | イーライ リリー アンド カンパニー | グリコール結合ｆｇｆ−２１化合物 |
| DK1751184T3 (da) | 2004-05-13 | 2009-11-23 | Lilly Co Eli | FGF-21 fusionsproteiner |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| ES2542228T3 (es) | 2004-07-08 | 2015-08-03 | Novo Nordisk A/S | Marcas de prolongación polipeptídica que comprenden un resto de tetrazol |
| WO2006028714A1 (en) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| MX2007002616A (es) | 2004-09-02 | 2007-05-16 | Lilly Co Eli | Muteinas de factor de crecimiento de fibroblasto 21. |
| EP1814573B1 (en) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| US7655627B2 (en) | 2004-12-14 | 2010-02-02 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| US20080261875A1 (en) | 2005-01-21 | 2008-10-23 | Eli Lilly And Company | Method For Treating Cardiovascular Disease |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US20100022446A1 (en) | 2007-01-18 | 2010-01-28 | Novo Nordisk A/S | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity |
| PL2068909T3 (pl) | 2007-03-30 | 2012-09-28 | Ambrx Inc | Modyfikowane polipeptydy fgf-21 i ich zastosowanie |
| SI2068909T1 (sl) | 2007-03-30 | 2012-09-28 | Ambrx Inc | Modificirani fgf-21 polipeptidi in njihova uporaba |
| JP2010535781A (ja) | 2007-08-03 | 2010-11-25 | イーライ リリー アンド カンパニー | 肥満に対する処置 |
| US20100261637A1 (en) | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| CN100587073C (zh) | 2008-03-24 | 2010-02-03 | 吉林农大生物反应器工程有限公司 | 人成纤维细胞生长因子-21的重组表达 |
| EA024751B8 (ru) | 2008-06-04 | 2020-01-31 | Амген Инк. | Мутанты fgf21 и их применение |
| EP2358749B1 (en) | 2008-10-10 | 2018-07-18 | Amgen, Inc | Fgf21 mutants and uses thereof |
| WO2010065439A1 (en) | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
| ES2692495T3 (es) * | 2009-01-23 | 2018-12-03 | Novo Nordisk A/S | Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos |
| SMT202400036T1 (it) | 2009-05-05 | 2024-03-13 | Amgen Inc | Mutanti fgf21 e loro utilizzi |
| US20120052069A1 (en) * | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
| US20120172298A1 (en) | 2009-06-11 | 2012-07-05 | Novo Nordisk A/S | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
| US20120035099A1 (en) | 2009-06-11 | 2012-02-09 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
| JP2013533227A (ja) * | 2010-06-08 | 2013-08-22 | ノヴォ ノルディスク アー／エス | Ｆｇｆ２１類似体および誘導体 |
| CN103415300B (zh) * | 2010-07-20 | 2018-02-23 | 诺沃—诺迪斯克有限公司 | N‑末端修饰的fgf21化合物 |
| CA2845357A1 (en) * | 2011-08-31 | 2013-03-07 | Amgen Inc. | Method of treating or ameliorating type 1 diabetes using fgf21 |
| AU2013311777B2 (en) * | 2012-09-07 | 2018-02-01 | Sanofi | Fusion proteins for treating a metabolic syndrome |
| SG11201504815QA (en) * | 2012-12-27 | 2015-07-30 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
-
2015
- 2015-12-22 HU HUE15817847 patent/HUE044783T2/hu unknown
- 2015-12-22 CN CN201580069436.9A patent/CN107108709B/zh active Active
- 2015-12-22 PT PT15817847T patent/PT3236991T/pt unknown
- 2015-12-22 ES ES15817847T patent/ES2742503T3/es active Active
- 2015-12-22 JP JP2017533789A patent/JP6727210B2/ja active Active
- 2015-12-22 PL PL15817847T patent/PL3236991T3/pl unknown
- 2015-12-22 AU AU2015371056A patent/AU2015371056B2/en active Active
- 2015-12-22 KR KR1020177017682A patent/KR102427527B1/ko active Active
- 2015-12-22 TW TW104143111A patent/TWI681966B/zh active
- 2015-12-22 WO PCT/EP2015/080969 patent/WO2016102562A1/en not_active Ceased
- 2015-12-22 RS RSP20191106 patent/RS59154B1/sr unknown
- 2015-12-22 EP EP15817847.5A patent/EP3236991B1/en active Active
- 2015-12-22 HK HK18105587.8A patent/HK1246156B/en unknown
- 2015-12-22 MX MX2017007458A patent/MX377044B/es active IP Right Grant
- 2015-12-22 RU RU2017125050A patent/RU2729011C2/ru active
- 2015-12-22 HR HRP20191292TT patent/HRP20191292T1/hr unknown
- 2015-12-22 TW TW108144310A patent/TWI708781B/zh active
- 2015-12-22 MY MYPI2017701848A patent/MY181181A/en unknown
- 2015-12-22 DK DK15817847.5T patent/DK3236991T3/da active
- 2015-12-22 SI SI201530859T patent/SI3236991T1/sl unknown
- 2015-12-22 AR ARP150104256A patent/AR103246A1/es active IP Right Grant
-
2017
- 2017-03-08 US US15/453,617 patent/US9744213B2/en active Active
- 2017-05-22 IL IL252438A patent/IL252438B/en unknown
- 2017-06-01 ZA ZA2017/03768A patent/ZA201703768B/en unknown
- 2017-06-06 SA SA517381673A patent/SA517381673B1/ar unknown
- 2017-07-07 US US15/643,543 patent/US9895417B2/en active Active
- 2017-12-21 US US15/849,920 patent/US10124039B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX377044B (es) | Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos. | |
| MX392572B (es) | Compuestos del péptido yy (pyy) selectivos y sus usos. | |
| MX2016006053A (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
| CO7151525A2 (es) | Proteínas del factor 21 de crecimiento del fibroblasto | |
| PE20161170A1 (es) | Composiciones farmaceuticas que comprenden azd9291 | |
| EA201491856A1 (ru) | Терапевтическое применение белков фактора роста фибробластов 21 | |
| GT201300131A (es) | Metodos de tratamiento de trastornos asociados con el fgf21 | |
| PH12021551589A1 (en) | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| AR096789A1 (es) | Derivados de péptidos similares a glp-1 y usos de los mismos | |
| CL2015002835A1 (es) | Nuevos derivados de piridina | |
| EP3368059A4 (en) | TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) -1 ANALOGUE | |
| EA201791696A1 (ru) | Композиция для лечения веноокклюзионной болезни печени | |
| ES2850277R1 (es) | Composiciones de administración farmacéutica y usos de las mismas | |
| MX2018008645A (es) | Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| CL2021000129A1 (es) | Apirasas solubilizadas, métodos y usos | |
| EP3643784A4 (en) | RECOMBINANT HUMAN BASIC FIBROBLASTIC GROWTH FACTOR (RH-BFGF) AND PHARMACEUTICAL COMPOSITION INCLUDING RH-BFGF | |
| WO2015048188A8 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| MX2020005342A (es) | Compuestos de pirazolopiridinona. | |
| EA201790899A1 (ru) | Состав, содержащий спирулину и пальмитоилэтаноламид и/или их соли или их фармацевтически приемлемые производные и препараты из них, для применения в профилактике и/или лечении состояний гиперактивированных тканей | |
| MX2021003908A (es) | Polipeptidos de accion prolongada y metodos para su produccion y administracion. | |
| HK1245131A1 (zh) | 用於治疗炎症性疾病的包含十六酰胺乙醇pea和番茄红素的组合物 | |
| CO2018008626A2 (es) | Formulaciones de oritavancina | |
| MX2016014701A (es) | (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina. | |
| MX2015006997A (es) | Composicion farmaceutica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |